InsidersTradesSigma
申报总数
公司
▲ 买入（6 笔）
▼ 卖出（1 笔）
内部人交易记录
首席执行官已披露买入
6
已披露卖出
1
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the full record of transactions filed by Stein Jeffrey, 首席执行官. Officer active across 3 companies, notably Cidara Therapeutics, Inc.. In total, 18 filings have been published. Split: 6 buys · 1 sell. Total volume traded: €1.7m. History available since 18 August 2021. The latest transaction was disclosed on 2 March 2026 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Stein Jeffrey
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报18 总计
50,000 股@ US$32.9578100.0% 占其流量Common StockSEC:0001610717-26-000078:0
标准退出：2026年5月31日 (T+90)
270 股Common StockSEC:0001478831-26-000004:0
5,763 股@ US$221.5058.2% 占其流量Common StockSEC:0001478831-26-000005:0
33,072 股0Common StockSEC:0001478831-25-000004:0
2,285 股@ US$219.6055.0% 占其流量Common StockSEC:0001610618-25-000104:0
8,000 股@ US$13.2120.2% 占其流量Common StockSEC:0001628280-24-027720:0
标准退出：2024年9月5日 (T+90)
56,692 股@ US$0.697.4% 占其流量Common StockSEC:0001610618-24-000017:0
48,625 股Common StockSEC:0000899243-23-019362:0
50,000 股@ US$0.95779.1% 占其流量Common StockSEC:0001610618-23-000081:0
标准退出：2023年11月6日 (T+90)
271,750 股0Common StockSEC:0001610618-23-000034:0
50,000 股@ US$1.037110.0% 占其流量Common StockSEC:0001610618-23-000026:0
标准退出：2023年6月25日 (T+90)
7,000 股@ US$1.90100.0% 占其流量Common StockSEC:0000904454-23-000178:0
20,000 股0Common StockSEC:0000904454-23-000111:0
165,000 股0Common StockSEC:0001610618-22-000023:0
20,000 股0Common StockSEC:0000904454-22-000173:0
20,000 股0Common StockSEC:0001209191-22-002603:0
50,000 股@ US$1.590627.1% 占其流量Common StockSEC:0001610618-21-000108:0
标准退出：2022年2月10日 (T+90)
40,000 股@ US$1.72213.1% 占其流量Common StockSEC:0001209191-21-052546:0
标准退出：2021年11月16日 (T+90)
18 条申报中的 18 条
About Stein Jeffrey
Jeffrey Stein serves as Chief Executive Officer and Board Member at Cidara Therapeutics, Inc. and Paratek Pharmaceuticals, Inc. He oversees the strategic and operational direction of these companies, ensuring that growth objectives are met. Jeffrey has a strong background in the pharmaceutical sector, enabling him to effectively lead his teams towards operational excellence. His commitment to innovation and sustainability is central to his mission.
